Company: LNAI
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001731122-25-001544
Chunk: 114

Company: Lunai Bioworks Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 2
Chunk 114
---
proate), electroshock is delivered
transauricularly using stimulation at 50 Hz and 50 mA for 0.8 seconds with a pulse width of 10 milliseconds. The total number of hind
limb flexes, hind limb extensions, and mortality rate is monitored for 60 seconds following electroshock, as are other adverse events.
We screened BioS_831 at both a low and high dose and found that at 40 mg/kg of BioS_831 significantly increased latency time to tonic
seizure induction and significantly reduced the number of observed tonic extension seizures, as compared to vehicle control. Notably,
unlike the ASM Sodium Valproate, BioS_831 did not cause sedation or ataxia. Sodium Valproate (VPA) while effective in this model at this
concentration, results in high levels of neurotoxicity, and has been associated with multi-organ failure, underscoring the importance
of not observing negative neurological effects with our novel compound. Post-study PK analysis showed good distribution of BioS_831 into
the brains of the test animals (average brain to plasma ratio 0.68). Since the electroshock seizure model is not based on seizure induction
through hypofunction of KCC2, these findings suggest that our zebrafish epilepsy primary screening model is capable of identifying novel
compounds that show translation to mammalian generalized epilepsy models and suggest that BioS_831 could further be optimized as a potential
anti-epileptic therapeutic.

Additionally, during the course
of this study we screened approximately 100 known neuroactives in our zebrafish model including clinical anticonvulsants, antidepressants,
antipsychotics, and dopaminergic signaling activators and inhibitors. The result is both an experimental platform and coupled computational
model that can identify both neurotherapeutics and neurotoxins, the former through direct experimental screening, and the latter through
machine-learning based prediction based on chemical structure.

BioSymetrics intends to expand the use of its platform
across the biopharmaceutical and healthcare markets. The company is developing its technology in compliance with applicable healthcare
data privacy regulations, including HIPAA and GDPR, and is focused on building AI solutions that address the growing demand for robust,
transparent, and reliable applications of artificial intelligence in life sciences.

Our Intellectual Property

Patents and licenses are key to
our business. Our strategy is to file patent applications to protect technology, inventions,